Home » Topics » Regulatory » EMA

EMA
RSS

EMEA recommends continued vaccination with Gardasil

Feb. 23, 2009

FDA issues public health advisory for Raptiva, EMEA recommends suspension

Feb. 23, 2009

CHMP recommends granting marketing authorization to Nycomed's Pantozol Control

Feb. 20, 2009

Merck Sharp & Dohme withdraws MAA to EMEA for vorinostat MSD in CTCL

Feb. 19, 2009

CHMP recommends new indication for Nycomed's TachoSil

Dec. 29, 2008

CHMP recommends marketing authorization for Pfizer's Fablyn in osteoporosis

Dec. 29, 2008

Oncoscience withdraws Theraloc (nimotuzumab) marketing authorization application

Dec. 5, 2008

Further explanation of CHMP's negative opinion for Santhera's Sovrima for Friedreich's ataxia

Nov. 25, 2008

EMEA recommends temporary suspension of Acomplia marketing authorization in obese patients

Oct. 24, 2008

EMEA withdraws marketing authorization for Protopy in the European Union

Oct. 9, 2008

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...